PSN010 is the second clinical candidate to emerge from the company’s discovery research efforts in diabetes.
“We believe PSN010’s dual mechanism of action, which has been demonstrated in preclinical studies to reduce blood glucose levels, may ultimately offer a competitive therapeutic option for diabetes patients,” stated Dr Anker Lundemose, executive vice president of OSI.
This single-center, double-blind phase I study is scheduled to enroll up to 80 healthy volunteers. The study is designed to provide preliminary information on the safety, tolerability, pharmacokinetics and pharmacodynamics of PSN010.
Study results will assist in facilitating the design of a multiple dose study in healthy subjects and a phase II “proof-of-concept” clinical study in diabetes patients.